Navigation Links
Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
Date:11/7/2008

HOPKINTON, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that they will host a conference call on Friday, November 14th, 2008 at 9:00am ET to review the third quarter ending September 30, 2008 and discuss other matters related to the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

To access the conference call, please dial 877-718-5095 for domestic and 719-325-4818 for international calls. The code for this conference call is 3501954. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Friday, November 28, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact: Sharon Correia - 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com

Adam Friedman - 212-981-2529 ext. 18

Adam Friedman Associates

adam@adam-friedman.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... MELBOURNE, Australia (PRWEB) , ... February 23, 2017 , ... ... . With perseverance and disciplined exercise regime, the author was able to successfully recover. ... Vas-Don collates all relevant information for various sources on the principals of massage, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... approach, leads to fewer trips the emergency room, fewer hospital admissions, and better ... Journal of Managed Care® (AJMC®) finds. The study can be found here ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World Horse Expo ... Tom Seay and his production crew. Tom Seay’s program “Best of America by ... Saddle Sidekicks will be featured on April 6, 2017. After the broadcast, the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... presentations and one poster presentation at PittCon ... Chicago IL.  Pittcon is the world,s largest ... science and serves a wide array of ... sciences, pharmaceutical discovery and QA, food safety, ...
(Date:2/23/2017)... 23, 2017 The U.S. cannabis market ... for recreational use in 2016. According to a new report ... worth an estimated $7.2 billion in 2016 and is projected ... While adult recreational sales are projected to jump from $2.6 ... 25% CAGR. The market may grow faster as the estimate ...
(Date:2/23/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ( www.provectusbio.com ... dermatology biopharmaceutical company, today announced that it has appointed ... as special advisers to the Company,s Board of Directors.  ... on financial and corporate strategy. Provectus also ... up to $2.5 million from Eric Wachter , ...
Breaking Medicine Technology: